MD Stock Analysis: Mednax | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 2.205m USD | 12M Return: 94.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.6M
EPS Trend: 81.4%
Qual. Beats: 0
Rev. Trend: -82.4%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pediatrix Medical Group (formerly MEDNAX) is a U.S. health care services company that provides newborn, maternal-fetal, and pediatric subspecialty care. Its clinical offerings are delivered through a national network of affiliated physicians, nurse practitioners, midwives, sonographers, and other clinicians serving patients primarily in hospital settings such as neonatal intensive care units (NICUs), obstetrics units, and pediatric departments. The company also supports newborn hearing screening and related ancillary services. Founded in 1979 and headquartered in Sunrise, Florida, Pediatrix adopted its current name in July 2022.
The company operates on an affiliated-physician model, in which independent neonatal and maternal-fetal specialists contract with the group to deliver hospital-based clinical care, a structure that is common among U.S. physician practice management organizations. As a small-cap health care services provider listed on the NYSE under the ticker MD, Pediatrix generates revenue primarily through professional services billing for physician and clinician work performed in inpatient and outpatient settings.
- U.S. birth rate decline pressures NICU patient volumes
- Medicaid reimbursement changes impact NICU profit margins
- Anesthesia segment sale refocuses capital on core pediatrics
| Net Income: 174.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 1.73 > 1.0 |
| NWC/Revenue: 7.48% < 20% (prev 11.16%; Δ -3.69% < -1%) |
| CFO/TA 0.13 > 3% & CFO 259.1m > Net Income 174.2m |
| Net Debt (339.7m) to EBITDA (279.0m): 1.22 < 3 |
| Current Ratio: 1.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (83.1m) vs 12m ago -3.19% < -2% |
| Gross Margin: 25.80% > 18% (prev 23.38%; Δ 2.42% > 0.5%) |
| Asset Turnover: 95.07% > 50% (prev 99.13%; Δ -4.06% > 0%) |
| Interest Coverage Ratio: 8.78 > 6 (EBIT TTM 256.4m / Interest Expense TTM 29.2m) |
| A: 0.07 (Total Current Assets 587.0m - Total Current Liabilities 442.6m) / Total Assets 2.07b |
| B: -0.03 (Retained Earnings -53.6m / Total Assets 2.07b) |
| C: 0.13 (EBIT TTM 256.4m / Avg Total Assets 2.03b) |
| D: 0.74 (Book Value of Equity 878.6m / Total Liabilities 1.19b) |
| Altman-Z'' = 2.00 = BBB |
| DSRI: 0.96 (Receivables 237.0m/252.8m, Revenue 1.93b/1.98b) |
| GMI: 0.91 (GM 23.38% / 25.80%) |
| AQI: 0.95 (AQ_t 0.68 / AQ_t-1 0.71) |
| SGI: 0.98 (Revenue 1.93b / 1.98b) |
| TATA: -0.04 (NI 174.2m - CFO 259.1m) / TA 2.07b) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 26.27 with a total of 436,710 shares traded. Over the past week, the price has changed by -1.83%, over one month by +11.50%, over three months by +22.47% and over the past year by +94.59%.
Current recommended Stop Loss: 25.30 (which is 3.7% or 1.2 ATR below the current price).
Mednax has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold MD.
- StrongBuy: 3
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.2 | -11.8% |
P/E Trailing = 13.034
P/E Forward = 8.2102
P/S = 1.1389
P/B = 2.5602
P/EG = 0.2433
Revenue TTM = 1.93b USD
EBIT TTM = 256.4m USD
EBITDA TTM = 279.0m USD
Long Term Debt = 398.3m USD (from longTermDebt, last quarter)
Short Term Debt = 204.3m USD (from shortTermDebt, last quarter)
Debt = 668.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 38.9m
Net Debt = 339.7m USD (calculated: Debt 668.7m - CCE 329.0m)
Enterprise Value = 2.54b USD (2.20b + Debt 668.7m - CCE 329.0m)
Interest Coverage Ratio = 8.78 (Ebit TTM 256.4m / Interest Expense TTM 29.2m)
EV/FCF = 10.71x (Enterprise Value 2.54b / FCF TTM 237.7m)
FCF Yield = 9.34% (FCF TTM 237.7m / Enterprise Value 2.54b)
FCF Margin = 12.30% (FCF TTM 237.7m / Revenue TTM 1.93b)
Net Margin = 9.02% (Net Income TTM 174.2m / Revenue TTM 1.93b)
Gross Margin = 25.80% ((Revenue TTM 1.93b - Cost of Revenue TTM 1.43b) / Revenue TTM)
Gross Margin QoQ = 23.72% (prev 24.37%)
Tobins Q-Ratio = 1.23 (Enterprise Value 2.54b / Total Assets 2.07b)
Interest Expense / Debt = 4.37% (Interest Expense 29.2m / Debt 668.7m)
Taxrate = 23.31% (53.0m / 227.2m)
NOPAT = 196.6m (EBIT 256.4m * (1 - 23.31%))
Current Ratio = 1.33 (Total Current Assets 587.0m / Total Current Liabilities 442.6m)
Debt / Equity = 0.76 (Debt 668.7m / totalStockholderEquity, last quarter 878.6m)
Debt / EBITDA = 1.22 (Net Debt 339.7m / EBITDA 279.0m)
Debt / FCF = 1.43 (Net Debt 339.7m / FCF TTM 237.7m)
Total Stockholder Equity = 867.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.57% (Net Income 174.2m / Total Assets 2.07b)
RoE = 20.09% (Net Income TTM 174.2m / Total Stockholder Equity 867.2m)
RoCE = 20.26% (EBIT 256.4m / Capital Employed (Equity 867.2m + L.T.Debt 398.3m))
RoIC = 11.33% (NOPAT 196.6m / Invested Capital 1.74b)
WACC = 5.75% (E(2.20b)/V(2.87b) * Re(6.48%) + D(668.7m)/V(2.87b) * Rd(4.37%) * (1-Tc(0.23)))
Discount Rate = 6.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 11.11 | Cagr: -0.50%
[DCF] Terminal Value 77.97% ; FCFF base≈220.3m ; Y1≈252.6m ; Y5≈371.7m
[DCF] Fair Price = 63.98 (EV 5.59b - Net Debt 339.7m = Equity 5.25b / Shares 82.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 81.39 | EPS CAGR: 21.04% | SUE: 0.78 | # QB: 0
Revenue Correlation: -82.40 | Revenue CAGR: -1.73% | SUE: 1.38 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.59 | Chg30d=+0.00% | Revisions=+22% | Analysts=7
EPS next Quarter (2026-09-30): EPS=0.67 | Chg30d=+0.00% | Revisions=-12% | Analysts=7
EPS current Year (2026-12-31): EPS=2.28 | Chg30d=+0.00% | Revisions=+44% | GrowthEPS=+11.6% | GrowthRev=+1.3%
EPS next Year (2027-12-31): EPS=2.36 | Chg30d=+0.00% | Revisions=+29% | GrowthEPS=+3.7% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: +29% (up=14, down=7)